Encompass Health Co. (NYSE:EHC) Holdings Decreased by Orchard Capital Management LLC

Orchard Capital Management LLC decreased its position in Encompass Health Co. (NYSE:EHC) by 1.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,105 shares of the company’s stock after selling 1,667 shares during the period. Encompass Health makes up approximately 3.7% of Orchard Capital Management LLC’s holdings, making the stock its 7th biggest position. Orchard Capital Management LLC owned 0.14% of Encompass Health worth $12,277,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of EHC. TD Asset Management Inc boosted its stake in Encompass Health by 239.6% in the 4th quarter. TD Asset Management Inc now owns 1,969,186 shares of the company’s stock worth $131,384,000 after purchasing an additional 1,389,275 shares in the last quarter. 8 Knots Management LLC bought a new position in Encompass Health during the 4th quarter valued at about $75,424,000. Norges Bank bought a new position in Encompass Health during the 4th quarter valued at about $69,178,000. Epoch Investment Partners Inc. lifted its stake in Encompass Health by 102.9% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,399,341 shares of the company’s stock valued at $93,364,000 after acquiring an additional 709,593 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in Encompass Health by 614.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 540,519 shares of the company’s stock valued at $44,637,000 after acquiring an additional 464,897 shares during the period. Institutional investors own 97.25% of the company’s stock.

Encompass Health Price Performance

Shares of NYSE:EHC opened at $92.06 on Friday. The firm’s 50 day moving average price is $89.80 and its 200-day moving average price is $85.08. The stock has a market capitalization of $9.27 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 1.39 and a beta of 0.88. Encompass Health Co. has a twelve month low of $57.55 and a twelve month high of $94.59. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 1.08.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Monday, August 5th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.10. Encompass Health had a net margin of 7.88% and a return on equity of 17.83%. The business had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.30 billion. During the same period last year, the firm posted $0.95 EPS. The company’s revenue was up 9.6% on a year-over-year basis. Equities research analysts expect that Encompass Health Co. will post 4.18 EPS for the current year.

Encompass Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, October 1st will be issued a dividend of $0.17 per share. This is a positive change from Encompass Health’s previous quarterly dividend of $0.15. This represents a $0.68 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend is Tuesday, October 1st. Encompass Health’s dividend payout ratio (DPR) is 18.38%.

Analysts Set New Price Targets

EHC has been the topic of several research analyst reports. Barclays lowered their target price on shares of Encompass Health from $113.00 to $109.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Leerink Partners initiated coverage on shares of Encompass Health in a research note on Wednesday, July 10th. They set an “outperform” rating and a $100.00 target price on the stock. UBS Group upped their target price on shares of Encompass Health from $96.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Stephens restated an “overweight” rating and set a $105.00 target price on shares of Encompass Health in a research note on Tuesday, August 6th. Finally, Leerink Partnrs upgraded shares of Encompass Health to a “strong-buy” rating in a research note on Wednesday, July 10th. Nine analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Encompass Health currently has an average rating of “Buy” and a consensus price target of $100.38.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, CFO Douglas E. Coltharp sold 12,260 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $86.34, for a total transaction of $1,058,528.40. Following the completion of the sale, the chief financial officer now directly owns 136,227 shares of the company’s stock, valued at approximately $11,761,839.18. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.10% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.